BioStock article: RA patients in great need of new treatment options

BioStock published an article on 5 May 2022 about the great need of new treatment options for RA patients.

Following the FDA’s safety warnings, a shift is seen away from JAK inhibitors for the treatment of rheumatoid arthritis. The changes in the market, and the need for new treatment options, highlight the possibilities for RA drugs under development with new mechanisms of action.

Although there is a variety of approved RA drugs on the market today, the need is still great for safer and more effective treatments for RA, as well as new treatment options for those who do not respond to currently available drugs. On the Nordic biotech map, there are several companies that specifically focus on this. One of them is Cyxone, a company developing the drug candidate Rabeximod, which is in phase II. Rabeximod targets inflammatory macrophages, a type of white blood cell that plays a central role in the inflammatory process.

Read the full article at biostock.se